Tag:

Shire

Latest Headlines

Latest Headlines

Flush-with-cash Shire revisits deal for NPS Pharma

Armed with a $1.64 billion breakup fee from former merger partner AbbVie and a brand-new $2.1 billion revolving loan facility, Shire looks ready to strike a deal. Rumor says it's revisiting some of its old targets, including New Jersey's NPS Pharmaceuticals.

Banks lost big betting on canceled AbbVie-Shire merger

The ripple effects of AbbVie's canceled Shire deal extend beyond the disgruntled hedge fund managers and spooked investors who've been making noise since the $55 billion buyout collapsed. Several large investment banks lost money, too, raising eyebrows over whether they're illegally betting their own funds.

Shire chief: We want to be like Gilead, Biogen and Celgene

On the rebound after a dalliance with AbbVie and its $55 billion red herring, Shire CEO Flemming Ornskov is back on the offensive, talking up his company's potential to rub elbows with the biggest among Big Biotech.

Shire CEO eyes $10B sales goal with more M&A deals in mind

Shire is enjoying the single life post-AbbVie breakup, touting its newly independent status and beefing up R&D. But if the company wants to beat its already ambitious sales goals, some strategic dealmaking could be on the horizon, CEO Flemming Ornskov says.

Shire says it's sitting on a $3B pipeline with M&A on tap

Shire, settling into life on its own after a failed merger with AbbVie, believes its in-development drugs can bring in a combined $3 billion in sales by 2020, sharpening its focus on rare diseases and keeping an eye out for bolt-on acquisitions.

Solo Shire moves 500 to Boston as it pushes ahead with reorg

More than 500 Pennsylvania-based Shire workers are shipping up to Boston in a move CEO Flemming Ornskov says will "streamline operations and drive further efficiencies."

Shire orders 500-plus staffers to move to Boston-area biotech 'Mecca'

Shire is following the biopharma trend of ditching far-flung outposts in favor of a centralized hub, shifting workers from its former U.S. headquarters in Pennsylvania to its Boston-area home base in a move the company believes will better align its sprawling business.

Why are M&A hedge funds gun shy? Blame AbbVie for killing its Shire deal

AbbVie can count this among the consequences of canceling its Shire buyout: Deal-focused hedge funds are losing investors.

Shire CEO happy to fly solo again after AbbVie deal's collapse

Post-Shire-breakup, AbbVie CEO Richard Gonzalez says his company will be scouting about for other "strategic" M&A hookups. But Shire chief Flemming Ornskov isn't interested in courting another buyer.

Billionaire Singer threatens to sue AbbVie over Shire breakup

A $1.64 billion breakup fee may have placated buyout target Shire after AbbVie pulled the plug on their $55 billion agreement. But investors? At least one may still be planning a little ax-grinding.